Abstract 1014 Figure 1

Intelligence method was developed to support the clinical staff in their decision with regards to tumor staging and to help them identifying the most complex cases where deeper analysis and discussion were required (e. g. conflicting information from different exams).

Result(s)* In the first round, the system has been used to retrieve all the eHR for the 96 patients with LACC. This was the training set of the study, with validated 2009 FIGO staging classification ranging from I B2 to IV A as output. For these patients, available eHR included MR, EUA, and PET-CT diagnostic reports. The system has been able to classify all patients belonging to the training set and - through the NLP procedures - the clinical features were analyzed and classified for each patient. A second important result was the setup of a predictive model to evaluate the patient's staging. Our approach has led to predict patient's staging within an accuracy of 94%. Lastly we created a user-oriented operational tool targeting the MTB who are confronted with the challenge of large volumes of patients to be diagnosed in the most accurate way. The resulting decision support system is summarized in figure 1. Furthermore, the MTB Smart DA was tested in a 13 LACC patients validation cohort showing an accuracy of 93%, in line with the training set performances.

Conclusion* This is the first proof of concept concerning the possibility of creating a smart virtual assistant for the MTB. A significant benefit could come from the integration of these automated methods in the collaborative, crucial decision stages.

1044

IMPACT OF COVID 19 ON ENDOMETRIAL CANCER FOLLOW-UP STRATEGIES

¹A Amirthanayagam*, ²L Boulter, ¹H Morris, ³T Miles, ⁴H Manderville, ¹E Moss. ¹University of Leicester, UK; ²Leicester Royal Infirmary, UK; ³Royal United Hospital, Bath, UK; ⁴Queen Elizabeth Hospital Gateshead, UK

10.1136/ijgc-2021-ESGO.326

Introduction/Background* The COVID-19 pandemic has had a dramatic impact on many aspects of healthcare, with changes in clinical practice aimed at reducing hospital appointments for patients who are classified as clinically vulnerable. In oncology this has resulted in a move towards the uptake of innovative follow-up schemes, such as patient-initiated or telephone follow-up, in particular for patients who are deemed to be at lower risk of recurrence. The aim of this study was to explore clinician's views of the impact of the COVID19 pandemic on the uptake of such schemes and the challenges in maintaining such schemes in the future.

Methodology A mixed methods study was performed consisting of an online questionnaire of clinical nurse specialists and a qualitative interview study of clinicians involved in the follow-up of patients after a diagnosis of endometrial cancer. The interviews were conducted virtually, audio recorded, transcribed verbatim and analysed using framework analysis.

Result(s)* In total, 22 clinical nurse specialists responded to the survey. Interview participants included gynaecological oncologists, cancer unit gynaecologist, oncologists and clinical nurse specialists. There was universal support to reduce face-to-face consultations during the COVID-19 pandemic and strong support for telephone and patient initiated follow-up. 70% of the participants of the online survey reported that in their opinion COVID-19 pandemic had had an impact on their clinic service by causing accelerated transition to patient initiated or telephone follow-up. The participants also reported patient support for the introduction of virtual follow-up compared to face-to-face appointments.

Conclusion* The COVID-19 pandemic has resulted in a transition towards telephone and patient initiated follow-up for the follow-up of endometrial cancer. Further research is needed to ensure that these schemes are able to address patients' clinical and information needs if the change from face-to-face clinical follow-up is to be continued following the COVID-19 pandemic.